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Lack of association of the
pregnane X receptor (PXR/
NR1I2) gene with inflammatory
bowel disease: parallel allelic
association study and gene wide
haplotype analysis
The pregnane X receptor gene (PXR/NR1I2)
regulates an array of genes involved in the
response to xenobiotics.1 2 Dysregulation of
this gene may critically influence intestinal
barrier defence and susceptibility to inflam-
matory bowel disease (IBD).3 Recent data
from Ireland have suggested strong associa-
tions between polymorphisms within the
PXR/NR1I2 gene and IBD. Dring et al per-
formed a case control study involving 422
patients with IBD (185 ulcerative colitis (UC)
and 237 (Crohn’s disease (CD)) and 350
healthy controls, using eight candidate poly-
morphisms in this gene.4 Highly significant
associations were demonstrated with UC, CD,
and IBD as a whole. This effect was most
significant for the two individual single
nucleotide polymorphisms (SNPs) in the
promoter region of this gene; compared
between the IBD cohort and controls,
rs3814055/223585 (p = 0.000008; odds ratio
(OR) 1.62 (95% confidence interval (CI)
1.31–2.00)) and rs1523127/224381
(p = 0.0002; OR 1.50 (95% CI 1.21–1.84)).
We have critically re-evaluated the con-
tribution of these allelic variants of
rs1523127/224381 of the PXR/NR1I2 gene
as determinants of disease susceptibility and
phenotype in the Scottish population. In
addition, we also performed a gene wide
association study using a haplotype tagging
strategy to assess in detail the overall
contribution of this gene to disease suscept-
ibility. A total of 387 UC and 328 CD patients,
together with 338 healthy controls (HC),
were studied. This study was designed to
have 98% power to replicate the previous
association with the rs1523127/224381 var-
iant (p,0.05). In the haplotype analysis, five
tagging SNPs (tSNPs) were selected using a
multimarker criterion, haplotype r2.0.80 to
predict all SNPs/haplotypes. This approach
was described by Weale and Goldstein and
was successfully applied in our previous
study of the ABCB1/MDR1 gene.5–8 The exons,
Table 1 Allelic and genotype frequencies of the selected five tagging single nucleotide polymorphisms (tSNPs)
dbSNP ID
position
Allele
(1/2) UC CD IBD HC
UC v HC
1 v 2
p value
odds ratio
95% CI
UC v HC
1/1 v 2/2
p value
odds ratio
95% CI
CD v HC
1 v 2
p value
odds ratio
95% CI
CD v HC
1/1 v 2/2
p value
odds ratio
95% CI
IBD v HC
1 v 2
p value
odds ratio
95% CI
IBD v HC
1/1 v 2/2
p value
odds ratio
95% CI
rs1523127
120983729
AA 139
(35.9%)
102
(31.1%)
241
(33.7%)
119
(35.6%)
0.96 0.91 0.69 1.00 0.82 1.00
AG 190
(49.1%)
186
(56.7%)
376
(52.6%)
167
(50.0%)
0.99 0.97 0.95 1.03 0.97 0.99
GG 58
(15.0%)
40
(12.2%)
98
(13.7%)
48
(14.4%)
0.80–1.22 0.61–1.52 0.76–1.19 0.62–1.69 0.81–1.17 0.66–1.49
A 468
(60.5%)
390
(59.5%)
858
(60.0%)
405
(60.6%)
G 306
(39.5%)
266
(40.5%)
572
(40.0%)
263
(39.4%)
rs2461823
121002815
CC 152
(40.9%)
132
(40.2%)
284
(40.6%)
119
(35.8%)
0.38 0.71 0.46 0.80 0.38 0.66
CT 175
(47.0%)
157
(47.9%)
332
(47.4%)
174
(52.4%)
1.11 1.11 1.09 1.10 1.09 1.10
TT 45
(12.1%)
39
(11.9%)
84
(12.0%)
39
(11.7%)
0.88–1.37 0.68–1.81 0.87–1.37 0.66–1.82 0.90–1.32 0.71–1.70
C 479
(64.4%)
421
(64.2%)
900
(64.3%)
412
(62.0%)
T 265
(35.6%)
235
(35.8%)
500
(35.7%)
252
(38.0%)
rs7643645
121008187
TT 143
(39.7%)
128
(43.2%)
271
(41.3%)
128
(38.5%)
0.79 0.90 0.82 0.62 0.73 0.91
TC 172
(47.8%)
120
(40.5%)
292
(44.5%)
168
(50.6%)
1.04 1.04 1.04 0.87 1.04 0.96
CC 45
(12.5%)
48
(16.2%)
93
(14.2%)
42
(12.6%)
0.84–1.29 0.64–1.69 0.82–1.30 0.54–1.42 0.86–1.26 0.63–1.46
T 458
(63.6%)
376
(63.5%)
834
(63.6%)
424
(62.7%)
C 262
(36.4%)
216
(36.5%)
478
(36.4%)
252
(37.3%)
rs1464603
121009039
AA 172
(45.9%)
153
(46.6%)
325
(46.3%)
167
(49.4%)
0.61 1.00 0.72 1.00 0.62 1.00
AG 159
(42.5%)
138
(42.1%)
297
(42.3%)
130
(38.5%)
0.94 0.98 0.96 1.01 0.95 0.99
GG 43
(11.5%)
37
(11.3%)
80
(11.4%)
41
(12.1%)
0.75–1.17 0.61–1.58 0.76–1.21 0.62–1.67 0.78–1.15 0.65–1.52
A 503
(67.2%)
444
(67.7%)
947
(67.5%)
464
(68.6%)
G 245
(32.8%)
212
(32.3%)
457
(32.5%)
212
(31.4%)
rs2472682
121015342
TT 42
(11.0%)
35
(11.1%)
77
(11.0%)
39
(11.7%)
0.65 1.00 0.63 0.70 0.97 0.82
TG 177
(46.2%)
129
(40.8%)
306
(43.8%)
140
(42.2%)
1.06 1.00 0.94 0.90 1.00 0.96
GG 164
(42.8%)
152
(48.1%)
316
(45.2%)
153
(46.1%)
0.84–1.32 0.62–1.64 0.74–1.19 0.54–1.50 0.82–1.22 0.62–1.47
T 261
(34.1%)
199
(31.5%)
460
(32.9%)
218
(32.8%)
G 505
(65.9%)
433
(68.5%)
938
(67.1%)
446
(67.2%)
UC, ulcerative colitis; CD, Crohn’s disease; HC, healthy controls; 95% CI, 95% confidence interval.
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promoter region, and intronic boundaries were
resequenced in 16 unrelated Centre d’Etude du
Polymorphisme Humain (CEPH) individuals
using 10 randomly spaced amplicons across the
PXR/NR1I2 gene. Haplotypes and their respec-
tive frequencies were constructed by further
genotyping in 32 CEPH trios.
No association was seen between
rs1523127/224381 (r2 = 0.96 with
rs3814055/223585) SNP and UC, CD, or
IBD (A-allelic frequency: 60.5% UC, 59.5%
CD, 60.0% IBD, and 60.6% HC; p = 0.96, 0.69,
and 0.82, respectively) (table 1). The signifi-
cant rs6785049 (27635) variant used in
Dring’s study was in strong linkage with
one of the tSNPs used in this study
(rs2472682, r2 = 0.86). In the Scottish data-
set, this SNP (rs2472682) was not associated
with IBD (T-allele: p = 0.97, OR 1.00 (95% CI
0.82–1.22); TT genotype: p = 0.82, OR 0.96
(95% CI 0.62–1.47)). Log likelihood analyses
comparing overall haplotypic distribution of
the five tSNPs demonstrated no associations
with UC, CD, or IBD (p = 0.90, 0.90, and 0.79,
respectively). There were no associations
observed between each of the five tSNPs
and the common constructed haplotypes
with UC, CD, and IBD, respectively.
Genotype-phenotype analyses using the
Montreal classification did not show any
associations with the studied variants or
haplotypes (full data available on request).
These negative data, based on a true
candidate gene approach, combine the use of
the single marker and multimarker haplotype
tagging approach and set a statistical limit to
the importance of the contribution of this gene
to disease susceptibility in our population.
Discordance between the findings of this study
and those data presented in Dring’s study
require clarification and explanation. When the
allelic frequencies and homozygosity rates of
the rs1523127/224381 SNP in these two
studies are compared, it is of interest to note
that differences in the conclusions between
these studies may be driven primarily by
differences in allelic and genotypic frequencies
in healthy controls studied in these datasets
(Scottish v Irish controls: A-allele frequencies:
60.6% v 54.8%, respectively, p = 0.03, OR 1.27
(95% CI 1.02–1.58); AA-genotype frequencies:
35.6% v 32.2%, respectively, p = 0.01, odds ratio
1.75 (95% CI 1.12–2.72)). Differences in
frequencies in the Scottish and Irish patient
populations were less marked (Scottish v Irish
cases: A-allele frequencies: 60.0% v 64.3%,
p = 0.05, OR 1.20 (95% CI 1.00–1.44); AA-
genotype frequencies: 33.7% v 41.1%, p = 0.17,
odds ratio 1.33 (95% CI 0.90–1.98)). Thus
potentially a number of explanations exist,
including cryptic population stratification,
genetic heterogeneity, or a type 1 error in the
initial dataset, each of which may explain the
divergent findings in these two populations, in
whom previous data had suggested consistent
founder effects.9 Further studies in these and
other Northern European populations may
help to resolve this issue formally.
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Genetic association between
factor V Leiden and coeliac
disease
We identified a family in which a previously
unknown genetic association between coeliac
disease (CD) and mutation of factor V (factor
V Leiden) occurred. The index case was a
young woman who abruptly presented with
severe ascites due to Budd-Chiari syndrome.
At endoscopy, she presented with a scalloped
duodenal mucosa suggestive of CD, further
confirmed by histology and serological tests.
Haematological assessment unveiled the
mutation of factor V due to the Arg506RGln
mutation at position 506.1 As shown in fig 1,
five siblings were also found to be affected by
CD (histology performed in all cases) and
were heterozygous carriers of factor V Leiden
for the same mutation. The two diseases
segregated as one in all cases while no sibling
was affected by only one of the two diseases.
This pattern of inheritance strongly suggests
that the genetic mutation responsible for the
onset of CD in this family occurs in a gene
which is in high linkage disequilibrium with
factor V gene, which is sited on the long arm
of chromosome 1. The penetrance of such a
gene in our family was found to be 100% as
all of the carriers demonstrated coeliac
disease at endoscopy.
Although susceptibility to CD is strongly
determined by environmental gluten, it is
clearly a common genetic disorder. HLA-DQ2
and HLA-DQ8 located in the MHC region on
chromosome 6 have been related to a genetic
predisposition to CD, although these genes
are also present in those not affected by CD.2
Dr Gwo-Tzer Ho was supported by the Chief
Scientist’s Office, Scottish Executive, UK (2001-04).
Dr Albert Tenesa is funded by Cancer Research UK
grant C348/A3758. Dr Elaine Nimmo and Mrs Hazel
Drummond are supported by a program grant from
the Wellcome Trust, C72789/Z/03/Z.
Conflict of interest: None declared.
A B1
2
3
4
C
D D
A = Refused screening
B = Dead from cerebral cancer
C = Index case
D = 2 and 4 years old not screened
 = Coeliac disease
= Factor V mutation
Figure 1 Genealogical tree of the family in which an association between factor V Leiden and
coeliac disease was unveiled.
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